The Omega-3 Index and Longevity: A Fatty-Acid Biomarker You Can Change

The index is the combined share of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in red-blood-cell membranes, reported as a percentage of total fatty acids. It was defined by Harris and von Schacky in 2004 as a standardized, reproducible way to capture long-term omega-3 status: red cells turn over roughly every three to four months, so their membrane content averages out day-to-day dietary swings. A finger-stick or venous sample is analysed by gas chromatography against a validated reference method.

Reported values are conventionally grouped as low (under about 4%), intermediate (4–8%) and high (above 8%). Those cut-points came from early cardiovascular research rather than a longevity trial, so they are best read as orientation, not targets. Membrane content is also what separates the index from a plasma omega-3 measurement, which is noisier and reflects the last few meals more than the last few months.

The largest analysis to date pooled 17 prospective cohorts — roughly 42,000 participants followed for a median of about 16 years — and found that people in the highest omega-3 category had meaningfully lower all-cause mortality than those in the lowest, alongside lower risk of death from cardiovascular disease (Harris et al., 2021). The gradient was continuous: risk fell across the range rather than switching at a single threshold.

In the Framingham Offspring cohort, a red-cell fatty-acid "fingerprint" in which EPA and DHA featured prominently predicted all-cause mortality about as well as some conventional risk factors (McBurney et al., 2021). Observational work like this consistently places a higher omega-3 index alongside longer survival — but it describes an association measured across populations, not a guaranteed outcome for any one person.

Cohort studies show that people with a higher index tend to live longer, yet they cannot prove the omega-3 itself is the cause — higher-index individuals also tend to eat more fish, smoke less, and differ in other ways. Randomized trials that hand out omega-3 supplements are the stricter test, and their results are mixed: large primary-prevention trials such as VITAL found only modest or non-significant effects on cardiovascular endpoints (Manson et al., 2019), while some trials using higher doses in higher-risk groups reported benefit.

A likely reason for the disagreement is baseline status and dose: a supplement moves the needle most in someone who starts low and takes enough to actually raise their membrane level. That is exactly why the index is more informative than the question "do you take fish oil?" — it measures where you actually are, not what you intend.

The index responds dose-dependently to EPA and DHA intake, whether from oily fish (salmon, sardines, mackerel, herring) or from supplements. Because absorption and metabolism vary between people, two individuals eating the same amount can land at different levels — which is why measuring beats assuming. Plant-derived ALA (from flax, walnuts, chia) converts to EPA and DHA only inefficiently, so it raises the index far less than pre-formed marine omega-3s.

That modifiability is the practical point. Among biomarkers linked to healthy aging, the omega-3 index is one of the few you can change through ordinary diet, and re-measuring after a few months shows whether a change actually landed. What the evidence supports is tracking and correcting a genuinely low level — not chasing an ever-higher number.